patient_id stringlengths 12 12 | record_id stringlengths 11 11 | cancer_type stringclasses 1
value | histology stringclasses 3
values | stage_at_diagnosis stringclasses 3
values | driver_mutation stringclasses 7
values | pd_l1_tps_percent int64 5 41 | tmb_mutations_per_mb float64 1.5 25 | age_at_diagnosis int64 38 90 | sex stringclasses 2
values | ecog_performance_status int64 0 4 | smoking_pack_years int64 0 111 | primary_tumor_size_cm float64 2 10 | metastatic_sites_count int64 0 11 | first_line_regimen stringclasses 6
values | overall_survival_months float64 4 83 | censored bool 2
classes | msi_status stringclasses 2
values | record_generation_timestamp stringdate 2026-03-15 05:35:56 2026-03-15 05:36:02 | synthetic_source stringclasses 1
value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ANODE_937172 | REC_0004901 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 29 | 13.2 | 71 | female | 2 | 12 | 4.7 | 4 | sotorasib 960 mg daily | 10.3 | false | MSI-H | 2026-03-15T05:35:58.058888+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_500411 | REC_0004902 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 26 | 10.9 | 60 | female | 1 | 19 | 5.2 | 6 | entrectinib 600 mg daily | 6.3 | true | MSS | 2026-03-15T05:35:58.059169+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_235048 | REC_0004903 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 26 | 7.6 | 62 | male | 0 | 1 | 5.9 | 1 | alectinib 600 mg BID | 33.3 | false | MSS | 2026-03-15T05:35:58.059409+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_925677 | REC_0004904 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 22 | 5.9 | 66 | female | 0 | 45 | 6.5 | 2 | carboplatin + paclitaxel + pembrolizumab | 11.8 | true | MSS | 2026-03-15T05:35:58.059649+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_466229 | REC_0004905 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 27 | 9.3 | 69 | female | 0 | 23 | 5 | 6 | carboplatin + paclitaxel + pembrolizumab | 13.2 | true | MSS | 2026-03-15T05:35:58.059883+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_104867 | REC_0004906 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 27 | 10.9 | 71 | male | 2 | 14 | 7.4 | 3 | sotorasib 960 mg daily | 5.7 | false | MSI-H | 2026-03-15T05:35:58.060180+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_952987 | REC_0004907 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 21 | 10 | 59 | female | 0 | 16 | 5.8 | 1 | alectinib 600 mg BID | 22.9 | false | MSI-H | 2026-03-15T05:35:58.060438+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_582145 | REC_0004908 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 27 | 5 | 74 | female | 2 | 62 | 4 | 6 | carboplatin + paclitaxel + pembrolizumab | 12 | true | MSS | 2026-03-15T05:35:58.060688+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_483883 | REC_0004909 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 35 | 13 | 51 | male | 0 | 30 | 5.5 | 6 | alectinib 600 mg BID | 19.2 | false | MSI-H | 2026-03-15T05:35:58.060927+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_842147 | REC_0004910 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 16 | 3.9 | 73 | female | 2 | 68 | 5.7 | 6 | carboplatin + paclitaxel + pembrolizumab | 16.3 | false | MSS | 2026-03-15T05:35:58.061163+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_979368 | REC_0004911 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 20 | 11.1 | 59 | female | 0 | 21 | 6.3 | 2 | alectinib 600 mg BID | 16.2 | true | MSI-H | 2026-03-15T05:35:58.061409+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_852997 | REC_0004912 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 25 | 8.4 | 70 | female | 1 | 25 | 6.8 | 6 | entrectinib 600 mg daily | 10.7 | true | MSS | 2026-03-15T05:35:58.061657+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_684813 | REC_0004913 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 22 | 13.9 | 51 | male | 0 | 2 | 7 | 8 | entrectinib 600 mg daily | 12.8 | false | MSI-H | 2026-03-15T05:35:58.061918+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_133989 | REC_0004914 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 28 | 9.3 | 74 | female | 1 | 62 | 5.7 | 2 | carboplatin + paclitaxel + pembrolizumab | 28.7 | true | MSS | 2026-03-15T05:35:58.062168+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_247040 | REC_0004915 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 22 | 6.9 | 72 | female | 2 | 75 | 4.9 | 3 | carboplatin + paclitaxel + pembrolizumab | 6.8 | false | MSS | 2026-03-15T05:35:58.062536+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_390508 | REC_0004916 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 27 | 12.8 | 85 | female | 1 | 16 | 5.5 | 6 | sotorasib 960 mg daily | 9.3 | true | MSI-H | 2026-03-15T05:35:58.062786+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_604033 | REC_0004917 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 18 | 6.7 | 77 | female | 2 | 53 | 2.8 | 6 | pembrolizumab 200 mg q3w | 11.8 | false | MSS | 2026-03-15T05:35:58.063028+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_941958 | REC_0004918 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 25 | 14.2 | 64 | male | 1 | 22 | 2.9 | 1 | alectinib 600 mg BID | 12.9 | false | MSS | 2026-03-15T05:35:58.063270+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_558591 | REC_0004919 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 22 | 10.7 | 57 | female | 0 | 15 | 5.1 | 2 | entrectinib 600 mg daily | 15.3 | false | MSI-H | 2026-03-15T05:35:58.063514+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_692937 | REC_0004920 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 25 | 6.2 | 82 | female | 2 | 62 | 5.1 | 2 | carboplatin + paclitaxel + pembrolizumab | 9.4 | false | MSS | 2026-03-15T05:35:58.063744+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_736235 | REC_0004921 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 29 | 11 | 70 | female | 2 | 21 | 6.7 | 1 | entrectinib 600 mg daily | 12.7 | false | MSI-H | 2026-03-15T05:35:58.063978+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_896418 | REC_0004922 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 29 | 11.7 | 69 | female | 1 | 11 | 5.1 | 6 | entrectinib 600 mg daily | 12.2 | false | MSI-H | 2026-03-15T05:35:58.064339+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_975237 | REC_0004923 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 29 | 12.7 | 70 | female | 1 | 12 | 4.6 | 0 | sotorasib 960 mg daily | 7.3 | false | MSI-H | 2026-03-15T05:35:58.064585+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_963334 | REC_0004924 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 28 | 17.1 | 61 | female | 1 | 19 | 3.6 | 6 | osimertinib 80 mg daily | 12.6 | true | MSS | 2026-03-15T05:35:58.064827+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_462286 | REC_0004925 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 24 | 8.7 | 69 | female | 1 | 15 | 5.9 | 5 | pembrolizumab 200 mg q3w | 15.4 | false | MSS | 2026-03-15T05:35:58.065061+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_618885 | REC_0004926 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 22 | 7.8 | 52 | male | 0 | 8 | 4.2 | 9 | osimertinib 80 mg daily | 13.4 | true | MSS | 2026-03-15T05:35:58.065293+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_818932 | REC_0004927 | Non-small cell lung cancer | Squamous cell carcinoma | III | None | 24 | 6.8 | 72 | female | 1 | 42 | 5.5 | 0 | carboplatin + paclitaxel + pembrolizumab | 44.8 | false | MSS | 2026-03-15T05:35:58.065526+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_381483 | REC_0004928 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 24 | 12.7 | 62 | female | 0 | 17 | 7.5 | 4 | alectinib 600 mg BID | 8.4 | false | MSS | 2026-03-15T05:35:58.065840+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_415224 | REC_0004929 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 14 | 9.6 | 74 | female | 2 | 13 | 4.9 | 6 | entrectinib 600 mg daily | 13.9 | false | MSS | 2026-03-15T05:35:58.066072+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_238015 | REC_0004930 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 19 | 6.3 | 64 | male | 1 | 35 | 6.1 | 7 | carboplatin + paclitaxel + pembrolizumab | 13.4 | true | MSS | 2026-03-15T05:35:58.066303+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_282830 | REC_0004931 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 23 | 13.8 | 71 | female | 0 | 18 | 4.3 | 6 | pembrolizumab 200 mg q3w | 6.4 | false | MSI-H | 2026-03-15T05:35:58.066535+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_408978 | REC_0004932 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 23 | 15.2 | 70 | female | 2 | 2 | 6.7 | 6 | alectinib 600 mg BID | 4 | false | MSS | 2026-03-15T05:35:58.066766+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_448846 | REC_0004933 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 19 | 15.1 | 70 | female | 2 | 6 | 6.3 | 5 | pembrolizumab 200 mg q3w | 17.5 | true | MSS | 2026-03-15T05:35:58.066996+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_666881 | REC_0004934 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 20 | 14.2 | 72 | female | 2 | 16 | 5.2 | 3 | entrectinib 600 mg daily | 10.3 | true | MSI-H | 2026-03-15T05:35:58.067230+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_511617 | REC_0004935 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 24 | 9.2 | 68 | male | 1 | 27 | 5.2 | 4 | pembrolizumab 200 mg q3w | 10.5 | true | MSS | 2026-03-15T05:35:58.067466+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_453916 | REC_0004936 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 35 | 7.6 | 67 | female | 0 | 44 | 7 | 5 | carboplatin + paclitaxel + pembrolizumab | 14.3 | true | MSS | 2026-03-15T05:35:58.067700+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_515010 | REC_0004937 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 27 | 5 | 66 | female | 1 | 43 | 4.7 | 1 | carboplatin + paclitaxel + pembrolizumab | 16.1 | false | MSS | 2026-03-15T05:35:58.067933+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_601593 | REC_0004938 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 31 | 15.7 | 67 | male | 1 | 22 | 4.7 | 1 | alectinib 600 mg BID | 8.2 | false | MSI-H | 2026-03-15T05:35:58.068202+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_642679 | REC_0004939 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None (PD-L1 high) | 20 | 5.2 | 56 | female | 1 | 61 | 6.2 | 2 | pembrolizumab 200 mg q3w | 18.5 | true | MSS | 2026-03-15T05:35:58.068442+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_685766 | REC_0004940 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 27 | 4.7 | 78 | female | 1 | 7 | 4.3 | 7 | alectinib 600 mg BID | 16 | false | MSS | 2026-03-15T05:35:58.068687+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_128215 | REC_0004941 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 33 | 8.7 | 80 | female | 2 | 10 | 6 | 2 | osimertinib 80 mg daily | 28.6 | true | MSS | 2026-03-15T05:35:58.068996+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_542175 | REC_0004942 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 26 | 14.2 | 69 | male | 0 | 23 | 6.2 | 4 | osimertinib 80 mg daily | 12.2 | true | MSS | 2026-03-15T05:35:58.069238+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_915368 | REC_0004943 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 29 | 20.8 | 75 | male | 2 | 25 | 5.2 | 7 | osimertinib 80 mg daily | 9.6 | false | MSS | 2026-03-15T05:35:58.069478+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_719571 | REC_0004944 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 26 | 10.6 | 73 | male | 2 | 12 | 4.6 | 1 | osimertinib 80 mg daily | 12.5 | true | MSI-H | 2026-03-15T05:35:58.069714+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_235565 | REC_0004945 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 16 | 3.7 | 69 | male | 1 | 38 | 5.4 | 2 | carboplatin + paclitaxel + pembrolizumab | 16.2 | true | MSS | 2026-03-15T05:35:58.069950+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_307764 | REC_0004946 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 23 | 13.7 | 81 | female | 2 | 19 | 6.7 | 2 | entrectinib 600 mg daily | 17 | false | MSI-H | 2026-03-15T05:35:58.070183+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_695642 | REC_0004947 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 26 | 16.3 | 67 | female | 0 | 27 | 6.7 | 1 | osimertinib 80 mg daily | 23.8 | false | MSI-H | 2026-03-15T05:35:58.070415+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_961030 | REC_0004948 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 26 | 6.4 | 64 | female | 1 | 6 | 4.2 | 7 | pembrolizumab 200 mg q3w | 12.3 | false | MSS | 2026-03-15T05:35:58.070647+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_457829 | REC_0004949 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 21 | 12.6 | 50 | male | 0 | 22 | 8.1 | 7 | entrectinib 600 mg daily | 15 | true | MSI-H | 2026-03-15T05:35:58.070881+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_715076 | REC_0004950 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 22 | 8 | 59 | female | 1 | 16 | 4.5 | 1 | sotorasib 960 mg daily | 27.2 | true | MSS | 2026-03-15T05:35:58.071113+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_761057 | REC_0004951 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 27 | 15.7 | 67 | female | 0 | 13 | 4.7 | 2 | osimertinib 80 mg daily | 13.2 | false | MSS | 2026-03-15T05:35:58.071348+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_989026 | REC_0004952 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None (PD-L1 high) | 23 | 6.2 | 61 | male | 1 | 82 | 6.4 | 2 | pembrolizumab 200 mg q3w | 23.2 | false | MSS | 2026-03-15T05:35:58.071582+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_762016 | REC_0004953 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 27 | 14.2 | 57 | male | 0 | 2 | 5.5 | 4 | entrectinib 600 mg daily | 7 | false | MSI-H | 2026-03-15T05:35:58.071818+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_420765 | REC_0004954 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 14 | 11.4 | 63 | male | 0 | 15 | 4.5 | 5 | entrectinib 600 mg daily | 8.7 | false | MSS | 2026-03-15T05:35:58.072201+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_243567 | REC_0004955 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 26 | 17 | 67 | female | 1 | 11 | 4.3 | 1 | alectinib 600 mg BID | 18.9 | false | MSI-H | 2026-03-15T05:35:58.072458+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_935244 | REC_0004956 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 27 | 10.5 | 66 | male | 0 | 16 | 7.1 | 2 | sotorasib 960 mg daily | 12.7 | true | MSS | 2026-03-15T05:35:58.072702+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_839922 | REC_0004957 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 25 | 4.7 | 68 | female | 0 | 27 | 5 | 5 | carboplatin + paclitaxel + pembrolizumab | 11.6 | false | MSS | 2026-03-15T05:35:58.072938+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_323354 | REC_0004958 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 25 | 7.2 | 70 | female | 1 | 10 | 4.7 | 1 | entrectinib 600 mg daily | 8.3 | true | MSS | 2026-03-15T05:35:58.073174+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_746230 | REC_0004959 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 24 | 6.1 | 66 | female | 0 | 35 | 4.5 | 1 | carboplatin + paclitaxel + pembrolizumab | 9.1 | false | MSS | 2026-03-15T05:35:58.073402+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_864746 | REC_0004960 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 35 | 12.4 | 83 | female | 3 | 23 | 5.4 | 1 | osimertinib 80 mg daily | 16.5 | false | MSS | 2026-03-15T05:35:58.073634+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_270829 | REC_0004961 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 31 | 14.5 | 55 | female | 1 | 5 | 5.3 | 7 | osimertinib 80 mg daily | 12.7 | false | MSS | 2026-03-15T05:35:58.073872+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_639021 | REC_0004962 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 22 | 10.5 | 72 | female | 2 | 16 | 5.3 | 5 | osimertinib 80 mg daily | 8.6 | false | MSS | 2026-03-15T05:35:58.074102+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_375163 | REC_0004963 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 18 | 16.6 | 63 | male | 0 | 24 | 6 | 5 | sotorasib 960 mg daily | 8.1 | true | MSS | 2026-03-15T05:35:58.074337+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_771599 | REC_0004964 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 28 | 5.9 | 66 | female | 0 | 32 | 7.3 | 1 | carboplatin + paclitaxel + pembrolizumab | 13.7 | false | MSS | 2026-03-15T05:35:58.074564+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_169434 | REC_0004965 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 14 | 10.2 | 73 | female | 2 | 11 | 5 | 1 | osimertinib 80 mg daily | 12.9 | false | MSS | 2026-03-15T05:35:58.074795+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_922397 | REC_0004966 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 20 | 4.4 | 72 | female | 1 | 11 | 6.8 | 5 | pembrolizumab 200 mg q3w | 14.1 | false | MSS | 2026-03-15T05:35:58.075021+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_107822 | REC_0004967 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 27 | 11.5 | 75 | female | 1 | 21 | 6 | 3 | osimertinib 80 mg daily | 8 | true | MSS | 2026-03-15T05:35:58.075315+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_357747 | REC_0004968 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 16 | 6.6 | 69 | female | 0 | 31 | 5.3 | 6 | pembrolizumab 200 mg q3w | 17.4 | false | MSS | 2026-03-15T05:35:58.075544+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_457018 | REC_0004969 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 23 | 7.9 | 72 | female | 1 | 22 | 5.6 | 7 | osimertinib 80 mg daily | 9.8 | false | MSS | 2026-03-15T05:35:58.075774+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_140897 | REC_0004970 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 28 | 14.7 | 59 | male | 0 | 19 | 3.4 | 1 | osimertinib 80 mg daily | 21.8 | true | MSI-H | 2026-03-15T05:35:58.076010+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_738432 | REC_0004971 | Non-small cell lung cancer | Adenocarcinoma | III | ROS1 fusion | 29 | 9.1 | 52 | female | 0 | 13 | 5.6 | 0 | entrectinib 600 mg daily | 45.1 | true | MSS | 2026-03-15T05:35:58.076349+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_282786 | REC_0004972 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 16 | 13.2 | 74 | female | 2 | 10 | 5.2 | 5 | sotorasib 960 mg daily | 12 | true | MSI-H | 2026-03-15T05:35:58.076588+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_220002 | REC_0004973 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 24 | 9.9 | 55 | female | 1 | 13 | 5.8 | 4 | pembrolizumab 200 mg q3w | 13.6 | false | MSS | 2026-03-15T05:35:58.076823+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_563210 | REC_0004974 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 21 | 4.4 | 72 | female | 2 | 39 | 3.9 | 1 | carboplatin + paclitaxel + pembrolizumab | 23.7 | false | MSS | 2026-03-15T05:35:58.077051+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_174223 | REC_0004975 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 20 | 6.5 | 69 | female | 0 | 56 | 7 | 1 | carboplatin + paclitaxel + pembrolizumab | 21.8 | true | MSS | 2026-03-15T05:35:58.077284+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_517534 | REC_0004976 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 21 | 7.7 | 67 | female | 1 | 12 | 6 | 7 | osimertinib 80 mg daily | 17.5 | false | MSS | 2026-03-15T05:35:58.077515+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_500931 | REC_0004977 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 30 | 5.7 | 74 | female | 1 | 17 | 4.5 | 1 | alectinib 600 mg BID | 18.1 | true | MSS | 2026-03-15T05:35:58.077746+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_838769 | REC_0004978 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 30 | 15.6 | 77 | female | 2 | 12 | 5 | 6 | alectinib 600 mg BID | 12.9 | true | MSI-H | 2026-03-15T05:35:58.077977+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_511654 | REC_0004979 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 24 | 13.5 | 63 | male | 0 | 6 | 4.3 | 3 | entrectinib 600 mg daily | 14.4 | false | MSI-H | 2026-03-15T05:35:58.078212+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_370344 | REC_0004980 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 23 | 14.5 | 64 | male | 1 | 32 | 4.1 | 5 | osimertinib 80 mg daily | 16.7 | false | MSI-H | 2026-03-15T05:35:58.078519+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_434468 | REC_0004981 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 34 | 11 | 83 | female | 1 | 10 | 7.6 | 9 | osimertinib 80 mg daily | 13 | false | MSI-H | 2026-03-15T05:35:58.078754+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_768777 | REC_0004982 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 23 | 6.9 | 66 | female | 1 | 51 | 7 | 1 | carboplatin + paclitaxel + pembrolizumab | 21 | false | MSS | 2026-03-15T05:35:58.078981+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_764595 | REC_0004983 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 26 | 17.5 | 70 | female | 2 | 24 | 5.8 | 5 | sotorasib 960 mg daily | 13.6 | true | MSI-H | 2026-03-15T05:35:58.079218+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_773507 | REC_0004984 | Non-small cell lung cancer | Adenocarcinoma | IVA | None (PD-L1 high) | 27 | 10.8 | 62 | female | 1 | 18 | 7.8 | 2 | pembrolizumab 200 mg q3w | 21.9 | false | MSS | 2026-03-15T05:35:58.079461+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_780196 | REC_0004985 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 35 | 16.9 | 72 | male | 2 | 7 | 2.7 | 2 | osimertinib 80 mg daily | 19.2 | true | MSS | 2026-03-15T05:35:58.079713+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_901185 | REC_0004986 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 14 | 8 | 74 | female | 2 | 58 | 6.2 | 6 | carboplatin + paclitaxel + pembrolizumab | 9 | true | MSS | 2026-03-15T05:35:58.079953+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_108368 | REC_0004987 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 29 | 12.5 | 66 | female | 1 | 7 | 6.8 | 0 | alectinib 600 mg BID | 14.3 | true | MSI-H | 2026-03-15T05:35:58.080231+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_740066 | REC_0004988 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 24 | 6.8 | 61 | male | 1 | 6 | 7.8 | 6 | entrectinib 600 mg daily | 10.6 | false | MSS | 2026-03-15T05:35:58.080477+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_628940 | REC_0004989 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 23 | 9.7 | 79 | female | 2 | 13 | 7.3 | 1 | sotorasib 960 mg daily | 19.1 | true | MSS | 2026-03-15T05:35:58.080727+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_718415 | REC_0004990 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 29 | 11.2 | 70 | male | 2 | 7 | 6.3 | 2 | sotorasib 960 mg daily | 20.6 | true | MSS | 2026-03-15T05:35:58.080987+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_776489 | REC_0004991 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 23 | 8.6 | 84 | female | 1 | 28 | 6.6 | 4 | carboplatin + paclitaxel + pembrolizumab | 10 | false | MSS | 2026-03-15T05:35:58.081235+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_106849 | REC_0004992 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 20 | 15 | 76 | female | 3 | 21 | 7 | 3 | alectinib 600 mg BID | 9.9 | true | MSI-H | 2026-03-15T05:35:58.081492+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_149383 | REC_0004993 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 24 | 11.2 | 78 | female | 1 | 12 | 5.3 | 2 | alectinib 600 mg BID | 6.6 | false | MSS | 2026-03-15T05:35:58.081852+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_482570 | REC_0004994 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 25 | 9.9 | 84 | female | 1 | 7 | 6.4 | 7 | osimertinib 80 mg daily | 12.4 | true | MSS | 2026-03-15T05:35:58.082093+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_489383 | REC_0004995 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 20 | 4 | 78 | female | 1 | 78 | 6 | 2 | carboplatin + paclitaxel + pembrolizumab | 25.7 | true | MSS | 2026-03-15T05:35:58.082333+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_136617 | REC_0004996 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 30 | 14 | 55 | male | 1 | 17 | 6.7 | 6 | osimertinib 80 mg daily | 12.5 | true | MSS | 2026-03-15T05:35:58.082569+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_364612 | REC_0004997 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 26 | 5.9 | 74 | male | 3 | 19 | 5.2 | 5 | pembrolizumab 200 mg q3w | 12.8 | false | MSS | 2026-03-15T05:35:58.082802+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_870600 | REC_0004998 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 31 | 9.3 | 52 | female | 0 | 13 | 6.8 | 3 | alectinib 600 mg BID | 14.1 | true | MSS | 2026-03-15T05:35:58.083035+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_383258 | REC_0004999 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 21 | 14.5 | 65 | female | 1 | 11 | 4 | 6 | sotorasib 960 mg daily | 11.8 | false | MSS | 2026-03-15T05:35:58.083272+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_379252 | REC_0005000 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 29 | 9.1 | 66 | female | 0 | 12 | 4 | 7 | pembrolizumab 200 mg q3w | 12.1 | true | MSS | 2026-03-15T05:35:58.083501+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.